復銳醫療科技(01696.HK)斥260萬人幣參投天津星絲奕生物
復銳醫療科技(01696.HK)公佈,於1月10日與復星健康 基金(蘇州)及復星健康基金(天津)訂立投資協議,擬設立天津星絲奕生物科技,註冊資本爲250萬元人民幣(下同),各方總投資金額爲2,500萬元,其中公司同意出資260萬元,將持有目標公司的已發行股份總數約10.4%。
天津星絲奕生物將成立從事絲素蛋白透明質酸鈉複合凝膠及面部埋線產品的研發、技術服務及供應。公司預期,將提升其醫療美容專業知識及探索交叉銷售機會。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.